A two-drug model for etoposide action against human topoisomerase IIalpha (Q38359958)

2 September 2017

A two-drug model for etoposide action against human topoisomerase IIalpha (English)

1 reference

2 September 2017

1 reference

3

Neil Osheroff

1 reference

2 September 2017

2

Alex B Burgin

1 reference

2 September 2017

Kenneth D Bromberg

1

1 reference

PubMed ID

12473657

2 September 2017

language of work or name

English

0 references

publication date

8 December 2002

1 reference

Journal of Biological Chemistry

2 September 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

2 September 2017

278

1 reference

2 September 2017

9

1 reference

2 September 2017

7406-7412

1 reference

Etoposide: four decades of development of a topoisomerase II inhibitor

2 September 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Tumor cell death induced by topoisomerase-targeting drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

DNA topoisomerase II as a target for cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

DNA topoisomerases: structure, function, and mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Cellular roles of dna topoisomerases: a molecular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Structure and mechanism of DNA topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Structure of DNA topoisomerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Mutagenic properties of topoisomerase-targeted drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

The critical role of chromosome translocations in human leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Human topoisomerase IIalpha possesses an intrinsic nucleic acid specificity for DNA ligation. Use of 5' covalently activated oligonucleotide substrates to study enzyme mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Positioning the 3'-DNA terminus for topoisomerase II-mediated religation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Complex formation between ethidium bromide and nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Apurinic sites are position-specific topoisomerase II poisons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

DNA sequence selectivity of topoisomerases and topoisomerase poisons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Vascular factors in cognitive impairment--where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Topoisomerase I-mediated DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Maternal diet and infant leukemia: A role for DNA topoisomerase II inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisom

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Mechanism of quinolone action. A drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Identification of active site residues in the "GyrA" half of yeast DNA topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Investigating the biological functions of DNA topoisomerases in eukaryotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Cell death induced by topoisomerase-targeted drugs: more questions than answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Clinical applications of anticancer drugs targeted to topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Type II DNA topoisomerase from Saccharomyces cerevisiae is a stable dimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Secondary leukemias induced by topoisomerase-targeted drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Catalytic inhibitors of DNA topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Differential in vitro interactions of a series of clinically useful topoisomerase-interacting compounds with the cleavage/religation activity of the human topoisomerase IIalpha and IIbeta isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Spontaneous DNA lesions poison human topoisomerase IIalpha and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

DNA cleavage and religation by human topoisomerase II alpha at high temperature

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

Translating the knowledge of molecular alterations that occur during colon carcinogenesis into clinically relevant solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

The response of eukaryotic topoisomerases to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M212056200

21 January 2018

Identifiers

DOI

10.1074/JBC.M212056200

1 reference

2 September 2017

1 reference

PubMed ID

12473657